{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:21:50Z","timestamp":1788211310987,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400917"],"award-info":[{"award-number":["82400917"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02688-0","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T06:02:18Z","timestamp":1756447338000},"page":"33-45","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bibliometrics in thyroid eye disease"],"prefix":"10.1007","volume":"49","author":[{"given":"YuanPing","family":"Hai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QinTao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijie","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Luffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0441-430X","authenticated-orcid":false,"given":"George J.","family":"Kahaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"2688_CR1","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A et al (2021) The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol 185:G43\u2013G67","journal-title":"Eur J Endocrinol"},{"key":"2688_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ et al (2016) The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy guidelines for the management of Graves\u2019 orbitopathy. Eur Thyroid J 5:9\u201326","journal-title":"Eur Thyroid J"},{"key":"2688_CR3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1530\/EJE-07-0666","volume":"158","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P et al (2008) Consensus statement of the European group on Graves\u2019 orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273\u2013285","journal-title":"Eur J Endocrinol"},{"key":"2688_CR4","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1089\/thy.2022.0251","volume":"32","author":"HB Burch","year":"2022","unstructured":"Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ et al (2022) Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Thyroid 32:1439\u20131470","journal-title":"Thyroid"},{"key":"2688_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1089\/thy.2022.0173","volume":"32","author":"YP Hai","year":"2022","unstructured":"Hai YP, Saeed MEM, Ponto KA, Elflein HM, Lee ACH et al (2022) A multicenter, single-blind, case-control, immunohistochemical study of orbital tissue in thyroid eye disease. Thyroid 32:1547\u20131558","journal-title":"Thyroid"},{"key":"2688_CR6","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"Smith TJ, Hegedus L (2016) Graves\u2019 disease. N Engl J Med 375:1552\u20131565","journal-title":"N Engl J Med"},{"key":"2688_CR7","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS (2010) Graves\u2019 ophthalmopathy. N Engl J Med 362:726\u2013738","journal-title":"N Engl J Med"},{"key":"2688_CR8","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40618-025-02556-x","volume":"48","author":"MS Matutinovic","year":"2025","unstructured":"Matutinovic MS, Vladimirov S, Gojkovic T, Djuricic I, Ciric J et al (2025) Analysis of non-cholesterol sterols and fatty acids in patients with graves\u2019 orbitopathy: insights into lipid metabolism in relation to the clinical phenotype of disease. J Endocrinol Invest 48:1333\u20131342","journal-title":"J Endocrinol Invest"},{"key":"2688_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70093","volume":"12","author":"Q Ma","year":"2024","unstructured":"Ma Q, Hai Y, Shen J (2024) Signatures of six autophagy-related genes as diagnostic markers of thyroid-associated ophthalmopathy and their correlation with immune infiltration. Immunity Inflamm Dis 12:e70093","journal-title":"Immunity Inflamm Dis"},{"key":"2688_CR10","first-page":"1103","volume":"46","author":"YP Hai","year":"2023","unstructured":"Hai YP, Lee ACH, Chen K, Kahaly GJ (2023) Traditional Chinese medicine in thyroid-associated orbitopathy. J Endocrinol Invest 46:1103\u20131113","journal-title":"J Endocrinol Invest"},{"key":"2688_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40618-019-01116-4","volume":"43","author":"YP Hai","year":"2020","unstructured":"Hai YP, Lee ACH, Frommer L, Diana T, Kahaly GJ (2020) Immunohistochemical analysis of human orbital tissue in Graves\u2019 orbitopathy. J Endocrinol Invest 43:123\u2013137","journal-title":"J Endocrinol Invest"},{"key":"2688_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1306232","volume":"14","author":"M Song","year":"2023","unstructured":"Song M, Sun W, Liu Q, Wang Z, Zhang H (2023) Global scientific trends on thyroid disease in early 21st century: a bibliometric and visualized analysis. Front Endocrinol (Lausanne) 14:1306232","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2688_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1252389","volume":"14","author":"B Song","year":"2023","unstructured":"Song B, Lin Z, Feng C, Zhao X, Teng W (2023) Global research landscape and trends of papillary thyroid cancer therapy: a bibliometric analysis. Front Endocrinol (Lausanne) 14:1252389","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2688_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1199563","volume":"14","author":"D Zheng","year":"2023","unstructured":"Zheng D, Yang Q, Wu J, Zhou Z, Cai J et al (2023) Global trends in research of endoscopic thyroidectomy from 2013 to 2022: a scientometric and visualization analysis. Front Endocrinol (Lausanne) 14:1199563","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2688_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1277739","volume":"14","author":"M Guo","year":"2023","unstructured":"Guo M, Li Q, Liu X, Wang Y, Yang Q et al (2023) Mapping the path towards novel treatment strategies: a bibliometric analysis of Hashimoto\u2019s thyroiditis research from 1990 to 2023. Front Endocrinol (Lausanne) 14:1277739","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2688_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/08820538.2023.2256838","volume":"39","author":"B Tao","year":"2024","unstructured":"Tao B, Micieli J (2024) The top 100 most-cited articles on thyroid eye disease: a bibliometric study. Semin Ophthalmol 39:123\u2013128","journal-title":"Semin Ophthalmol"},{"key":"2688_CR17","first-page":"590","volume":"85","author":"KA Elubous","year":"2022","unstructured":"Elubous KA, Alebous AD, Abous HA, Elubous RA, Alebous LA et al (2022) Trends in graves\u2019 orbitopathy research in the past two decades: a bibliometric analysis. Arq Bras Oftalmol 85:590\u2013598","journal-title":"Arq Bras Oftalmol"},{"key":"2688_CR18","doi-asserted-by":"publisher","first-page":"e24831","DOI":"10.2196\/24831","volume":"10","author":"J Cao","year":"2021","unstructured":"Cao J, Wang N, Hou S, Qi X, Chen Y et al (2021) Overview of graves ophthalmopathy literature from 1999 to 2019: bibliometric analysis. Interact J Med Res 10:e24831","journal-title":"Interact J Med Res"},{"key":"2688_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"NJ van Eck","year":"2010","unstructured":"van Eck NJ, Waltman L (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84:523\u2013538","journal-title":"Scientometrics"},{"key":"2688_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10071-020-01448-2","volume":"24","author":"M Aria","year":"2021","unstructured":"Aria M, Alterisio A, Scandurra A, Pinelli C, D\u2019Aniello B (2021) The scholar\u2019s best friend: research trends in dog cognitive and behavioral studies. Anim Cogn 24:541\u2013553","journal-title":"Anim Cogn"},{"key":"2688_CR21","doi-asserted-by":"publisher","first-page":"1361535","DOI":"10.3389\/fpsyt.2024.1361535","volume":"15","author":"Y Liu","year":"2024","unstructured":"Liu Y, Chen C, Zhou Y, Zhang N, Liu S (2024) Twenty years of research on borderline personality disorder: a scientometric analysis of hotspots, bursts, and research trends. Front Psychiatry 15:1361535","journal-title":"Front Psychiatry"},{"key":"2688_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ et al (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382:341\u2013352","journal-title":"N Engl J Med"},{"key":"2688_CR23","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA et al (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376:1748\u20131761","journal-title":"N Engl J Med"},{"key":"2688_CR24","first-page":"168","volume":"21","author":"L Bartalena","year":"2000","unstructured":"Bartalena L, Pinchera A, Marcocci C (2000) Management of graves\u2019 ophthalmopathy: reality and perspectives. Endocr Rev 21:168\u2013199","journal-title":"Endocr Rev"},{"key":"2688_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf) 47:9\u201314","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2688_CR26","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/bjo.73.8.639","volume":"73","author":"MP Mourits","year":"1989","unstructured":"Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A et al (1989) Clinical criteria for the assessment of disease activity in graves\u2019 ophthalmopathy: a novel approach. Br J Ophthalmol 73:639\u2013644","journal-title":"Br J Ophthalmol"},{"key":"2688_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.615993","volume":"11","author":"L Bartalena","year":"2020","unstructured":"Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML (2020) Epidemiology, natural history, risk factors, and prevention of graves\u2019 orbitopathy. Front Endocrinol (Lausanne) 11:615993","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2688_CR28","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA et al (2015) Randomized controlled trial of rituximab in patients with graves\u2019 orbitopathy. J Clin Endocrinol Metab 100:432\u2013441","journal-title":"J Clin Endocrinol Metab"},{"key":"2688_CR29","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi M, Vannucchi G, Curro N, Campi I, Covelli D et al (2015) Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 100:422\u2013431","journal-title":"J Clin Endocrinol Metab"},{"key":"2688_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/clinem\/dgad637","volume":"109","author":"RS Douglas","year":"2023","unstructured":"Douglas RS, Couch S, Wester ST, Fowler BT, Liu CY et al (2023) Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab 109:25\u201335","journal-title":"J Clin Endocrinol Metab"},{"key":"2688_CR31","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","volume":"129","author":"RS Douglas","year":"2021","unstructured":"Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA et al (2021) Teprotumumab efficacy, safety and durability in longer duration thyroid eye disease and retreatment: Optic-X study. Ophthalmology 129:438\u2013449","journal-title":"Ophthalmology"},{"key":"2688_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.653627","volume":"12","author":"TJ Smith","year":"2021","unstructured":"Smith TJ (2021) Insulin-like growth factor pathway and the thyroid. Front Endocrinol (Lausanne) 12:653627","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2688_CR33","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1089\/thy.2024.0606","volume":"35","author":"TJ Smith","year":"2025","unstructured":"Smith TJ (2025) Controversies surrounding IGF-I receptor involvement in Thyroid-associated ophthalmopathy. Thyroid 35:232\u2013244","journal-title":"Thyroid"},{"key":"2688_CR34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1210\/er.2018-00066","volume":"40","author":"TJ Smith","year":"2019","unstructured":"Smith TJ, Janssen J (2019) Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev 40:236\u2013267","journal-title":"Endocr Rev"},{"key":"2688_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1463379","volume":"15","author":"A George","year":"2024","unstructured":"George A, Lotz J, Luffy M, Ganz AL, Wolf J et al (2024) A novel bioassay for thyroid-blocking immunoglobulins. Front Endocrinol (Lausanne) 15:1463379","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2688_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00028","volume":"8","author":"GJ Kahaly","year":"2017","unstructured":"Kahaly GJ, Diana T (2017) TSH receptor antibody functionality and nomenclature. Front Endocrinol (Lausanne) 8:28","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2688_CR37","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1210\/jc.2016-1220","volume":"101","author":"GJ Kahaly","year":"2016","unstructured":"Kahaly GJ, Diana T, Glang J, Kanitz M, Pitz S et al (2016) Thyroid stimulating antibodies are highly prevalent in Hashimoto\u2019s thyroiditis and associated orbitopathy. J Clin Endocrinol Metab 101:1998\u20132004","journal-title":"J Clin Endocrinol Metab"},{"key":"2688_CR38","doi-asserted-by":"publisher","first-page":"e1006","DOI":"10.1210\/clinem\/dgz292","volume":"105","author":"GJ Kahaly","year":"2020","unstructured":"Kahaly GJ, Diana T, Kanitz M, Frommer L, Olivo PD (2020) Prospective trial of functional thyrotropin receptor antibodies in graves disease. J Clin Endocrinol Metab 105:e1006\u2013e1014","journal-title":"J Clin Endocrinol Metab"},{"key":"2688_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4158\/EP-2019-0363","volume":"26","author":"GJ Kahaly","year":"2020","unstructured":"Kahaly GJ, Diana T, Olivo PD (2020) Tsh receptor antibodies: relevance & utility. Endocr Pract 26:97\u2013106","journal-title":"Endocr Pract"},{"key":"2688_CR40","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1210\/jc.2018-02705","volume":"104","author":"GJ Kahaly","year":"2019","unstructured":"Kahaly GJ, Wuster C, Olivo PD, Diana T (2019) High titers of thyrotropin receptor antibodies are associated with orbitopathy in patients with graves disease. J Clin Endocrinol Metab 104:2561\u20132568","journal-title":"J Clin Endocrinol Metab"},{"key":"2688_CR41","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","volume":"9","author":"GJ Kahaly","year":"2021","unstructured":"Kahaly GJ, Douglas RS, Holt RJ, Sile S, Smith TJ (2021) Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol 9:360\u2013372","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2688_CR42","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1089\/thy.2023.0656","volume":"34","author":"GJ Kahaly","year":"2024","unstructured":"Kahaly GJ, Subramanian PS, Conrad E, Holt RJ, Smith TJ (2024) Long-term efficacy of teprotumumab in thyroid eye disease: follow-up outcomes in three clinical trials. Thyroid 34:880\u2013889","journal-title":"Thyroid"},{"key":"2688_CR43","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Pitz S, Hommel G, Dittmar M (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in graves\u2019 orbitopathy. J Clin Endocrinol Metab 90:5234\u20135240","journal-title":"J Clin Endocrinol Metab"},{"key":"2688_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","volume":"6","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, Riedl M, Konig J, Pitz S, Ponto K et al (2018) Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol 6:287\u2013298","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2688_CR45","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/MED.0000000000000493","volume":"26","author":"GJ Kahaly","year":"2019","unstructured":"Kahaly GJ (2019) Immunotherapies for thyroid eye disease. Curr Opin Endocrinol Diabetes Obes 26:250\u2013255","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2688_CR46","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1210\/clinem\/dgaa646","volume":"105","author":"GJ Kahaly","year":"2020","unstructured":"Kahaly GJ (2020) Management of graves\u2019 thyroidal and extrathyroidal disease - an update. J Clin Endocrinol Metab 105:3704\u20133720","journal-title":"J Clin Endocrinol Metab"},{"key":"2688_CR47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000490384","volume":"7","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K et al (2018) 2018 European Thyroid Association guideline for the management of Graves\u2019 hyperthyroidism. Eur Thyroid J 7:167\u2013186","journal-title":"Eur Thyroid J"},{"key":"2688_CR48","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M et al (2011) Selenium and the course of mild graves\u2019 orbitopathy. N Engl J Med 364:1920\u20131931","journal-title":"N Engl J Med"},{"key":"2688_CR49","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1177\/11206721231199367","volume":"34","author":"K Rana","year":"2024","unstructured":"Rana K, Garg D, Patel S, Selva D (2024) Imaging of dysthyroid optic neuropathy. Eur J Ophthalmol 34:1346\u20131354","journal-title":"Eur J Ophthalmol"},{"key":"2688_CR50","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s00330-021-08300-2","volume":"32","author":"M Zou","year":"2022","unstructured":"Zou M, Wu D, Zhu H, Huang X, Zhao X et al (2022) Multiparametric quantitative MRI for the evaluation of dysthyroid optic neuropathy. Eur Radiol 32:1931\u20131938","journal-title":"Eur Radiol"},{"key":"2688_CR51","doi-asserted-by":"publisher","first-page":"9203","DOI":"10.1007\/s00330-023-09848-x","volume":"33","author":"C Song","year":"2023","unstructured":"Song C, Luo Y, Huang W, Duan Y, Deng X et al (2023) Extraocular muscle volume index at the orbital apex with optic neuritis: A combined parameter for diagnosis of dysthyroid optic neuropathy. Eur Radiol 33:9203\u20139212","journal-title":"Eur Radiol"},{"key":"2688_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.991588","volume":"13","author":"C Song","year":"2022","unstructured":"Song C, Luo Y, Yu G, Chen H, Shen J (2022) Current insights of applying MRI in graves\u2019 ophthalmopathy. Front Endocrinol (Lausanne) 13:991588","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2688_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1356055","volume":"15","author":"C Yi","year":"2024","unstructured":"Yi C, Niu G, Zhang Y, Rao J, Liu G et al (2024) Advances in artificial intelligence in thyroid-associated ophthalmopathy. Front Endocrinol (Lausanne) 15:1356055","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2688_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1300196","volume":"14","author":"CL Chng","year":"2023","unstructured":"Chng CL, Zheng K, Kwee AK, Lee MH, Ting D et al (2023) Application of artificial intelligence in the assessment of thyroid eye disease (TED) - a scoping review. Front Endocrinol (Lausanne) 14:1300196","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02688-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02688-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02688-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:03:21Z","timestamp":1769501001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02688-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["2688"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02688-0","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}